Win for pharma in UK – zero US tariffs, VPAG rate cap and NICE threshold increase
On 1 December, the fortunes of the UK pharma sector changed radically, with the UK Government becoming the first in…
Pricing and Market Access
Slow progress as rare disease regulations in developing ASEAN states begin to take shape
Sri Lanka’s drug pricing reform: balancing affordability with sustainability
The threshold debate in Norway
Trump administration announces MFN drug pricing deal with Pfizer
Orphan drug landscape in the 7MM: launch patterns, market trends, and HTA insights
VPAG stalemate – how can the UK pharma market be rescued?
Morocco’s sweeping pharmaceutical pricing reform
